Advertisement
Advertisement

HALO

HALO logo

Halozyme Therapeutics, Inc.

68.52
USD
Sponsored
-0.46
-0.67%
May 21, 16:00 UTC -4
Closed
exchange

After-Market

68.01

-0.51
-0.74%

Halozyme Therapeutics, Inc. Profile

About

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.

Info & Links

CEO

Helen I. Torley

Headquarters

12390 EL CAMINO REAL
SAN DIEGO, CA 92130, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.halozyme.com

Auditor

Ernst & Young LLP

Share holders

179,868

Employees

423

Halozyme Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization2

8.07B

Enterprise Value

9.90B

Enterprise Value/EBITDA(ttm)

15.98

Price to Earnings Ratio(ttm)

17.75

Price to Sales(ttm)

5.69

Price to Book(mrq)

161.60

Price to Cash(ytd)

14.06

Profitability

Gross Margin(ttm)

83.62%

Operating Margin(ttm)

33.33%

Profit Margin(ttm)

28.35%

Return on Equity(ttm)

136.12%

Return on Invested Capital(ttm)

21.88%

Return on Assets(ttm)

20.69%

Income Statement

Revenue(ttm)

1.51B

Revenue Per Share(ttm)

12.72

Gross Profit(ttm)

1.25B

EBITDA(ttm)3

619.61M

Net Income Available to Common(ttm)

348.84M

Diluted EPS(ttm)

2.49

Share Statistics

Beta (5Y Monthly)

1.03

52-Week Change

28.19%

S&P 500 52-Week Change

27.39%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

118.61M

Dividend Yield

0.00%

Float4

115.51M

% Held by Insiders

2.50%

% Held by Institutions

97.79%

Balance Sheet

Total Cash(mrq)

318.62M

Total Cash Per Share(mrq)

2.69

Total Debt(mrq)

2.14B

Total Debt/Equity(mrq)

4389.38%

Current Ratio(mrq)

4.66%

Quick Ratio(mrq)

3.66%

Book Value Per Share(mrq)

0.41

Cash Flow

Operating Cash Flow Per Share(ytd)

5.26

Free Cash Flow(ytd)

644.59M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement